Jan 5 2011
Amyris, Inc. (NASDAQ: AMRS) announced today that it has signed definitive agreements with Glycotech, Inc. and Salisbury Partners, LLC for Glycotech to provide chemical processing at Salisbury’s Leland, NC facility to convert Amyris’s Biofene™, or renewable farnesene, into finished products for a wide range of applications.
The parties expect that Amyris’s No Compromise® squalane will be the first Amyris product processed for commercial sale in the facility. The facility can also provide finishing services for other Amyris renewable products, including industrial lubricants, polymers and transportation fuels. All products will be owned and distributed solely by Amyris.
This agreement with Glycotech complements Amyris’s existing production arrangements and provides Amyris with integrated capability from feedstock processing to the final product production process. Amyris expects that by controlling the final production step through the Glycotech relationship, it will be in a position to realize the economic benefits of expanded supply chain integration. Amyris has entered into agreements for the production of farnesene at a facility of Biomin GMBH located in Piracicaba, Brazil, and at a facility of Tate & Lyle located in Decatur, IL.
“We are excited to access this facility to perform our own chemical processing of farnesene into our target 2011 end products of squalane and lubricant,” said John Melo, CEO of Amyris. “In addition, we can expand these operations to grow beyond our 2011 needs to support growth in several of our vertical markets.”